No: 2017/SEC/NOV/150

November 07, 2017

National Stock Exchange of India Limited
"Exchange Plaza", 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex
Bandra (East), Mumbai – 400051

NSE - Symbol - BIOCON

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

BSE - Scrip code - 532523

Dear Sir,

Sub: Company Statement on Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA.

Please find below the Company's statement on the subject matter.

"Biocon's partner Mylan has resubmitted the Marketing Authorization Applications (MAAs) for our proposed biosimilar trastuzumab and pegfilgrastim with the European Medicines Agency (EMA) as per the administrative protocol. This follows the earlier withdrawal of both applications in response to the audit of our aseptic drug product facility by the designated European authority. Biocon has completed the Corrective and Preventive Actions (CAPAs), including the facility modifications, in response to the audit observations and expects these to be verified during re-inspection."

- Company Spokesperson

Kindly take on record the same.

Thanking You,

For BIOCON LIMITED

Rajiv Balakrishnan
Company Secretary